Psoriasis is a chronic, immune-mediated disease driven largely by the IL-23/Th17 inflammatory axis, resulting in the hyperproliferation and abnormal differentiation of keratinocytes that produces its characteristic thick, scaly plaques. It's also a disease where treatment intensity should track disease severity, and pharmacists are frequently the ones who notice when it doesn't.

The Treatment Ladder

Mild disease is typically managed with topical therapy: corticosteroids, vitamin D analogs (calcipotriene) often combined with a corticosteroid, and topical retinoids (tazarotene). Topical combination products are common specifically to reduce the total steroid burden while maintaining efficacy.

Moderate disease, or disease not adequately controlled topically, often moves to phototherapy (narrowband UVB) or systemic non-biologic agents such as methotrexate, apremilast, or cyclosporine.

Moderate-to-severe disease is increasingly managed with biologic therapy, targeting TNF-α, IL-17, or IL-23 depending on the agent (see our biologics overview for a breakdown by mechanism).

Counseling Points Worth Flagging

  • Topical fatigue is one of the most common reasons mild-to-moderate psoriasis under-responds. Refill gaps or early discontinuation are worth a conversation, not just a refill.
  • Phototherapy patients benefit from reinforcement on realistic timelines (weeks, not days) and the importance of consistent attendance for a cumulative effect.
  • Methotrexate requires folic acid supplementation to offset toxicity, along with monitoring themes that include hepatic function and, over time, cumulative dose tracking.
  • Apremilast commonly causes GI effects, particularly nausea and diarrhea, early in treatment; counseling on gradual dose titration and setting expectations improves adherence through the initial weeks.
  • Biologic therapy carries the monitoring and infection-risk counseling themes common to the class; see our biologics overview for specifics.

This is an educational overview and does not constitute medical or pharmaceutical advice. Treatment selection should always follow individualized clinical assessment and current prescribing information.